ECB to raise interest rates for first time since 2011
FT News Briefing
00:00
Trust Issues in the Chinese Vaccine Industry
This chapter examines the difficulties encountered by the Chinese vaccine industry, emphasizing its history of poor quality and insufficient transparency about adverse effects. Focusing on the Sinovac COVID vaccine, it discusses the lack of critical information on side effects and explores an insurance scheme intended to enhance public trust in vaccinations amidst concerns over compensation complexities.
Play episode from 06:44
Transcript
